Monocyte-to-high-density lipoprotein ratio and systemic immune-inflammation index: Potential parameters for the evaluation of disease activity and severity in Graves’ ophthalmopathy?
Purpose To assess changes in monocyte-to-high-density lipoprotein (HDL) ratio (MHR), neutrophil-to-lymphocyte ratio (NLR), and systemic immune-inflammation index (SII) with Graves’ ophthalmopathy (GO) and their possible relation with GO disease activity and severity. Methods A total of 20 patients w...
Gespeichert in:
Veröffentlicht in: | International ophthalmology 2024-03, Vol.44 (1), p.154-154, Article 154 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Purpose
To assess changes in monocyte-to-high-density lipoprotein (HDL) ratio (MHR), neutrophil-to-lymphocyte ratio (NLR), and systemic immune-inflammation index (SII) with Graves’ ophthalmopathy (GO) and their possible relation with GO disease activity and severity.
Methods
A total of 20 patients with GO and 24 healthy controls were involved in the study. The thyroid status, MHR (monocyte count/HDL cholesterol level), NLR (neutrophil count/lymphocyte count) and SII [(neutrophil count × platelet count)/lymphocyte count] were compared between the groups. The relation of systemic inflammation parameters with disease activity and severity was evaluated.
Results
The mean Clinical Activity Score (CAS) was 0.75 ± 0.78 in the GO group. None of the patients were active. The severity was mild for 14 (70.0%) patients and moderate-to-severe for 6 (30.0%) patients. MHR (17.28 ± 5.56 vs. 13.28 ± 5.08), NLR (2.51 ± 1.09 vs. 1.69 ± 0.53) and SII [600.42 (391.79–837.16) vs. 413.69 (344.26–603.82)] values were significantly increased in GO patients than in the controls (
p
= 0.017,
p
= 0.005 and
p
= 0.036, respectively). CAS was significantly correlated with MHR (r = 0.815,
p
|
---|---|
ISSN: | 1573-2630 0165-5701 1573-2630 |
DOI: | 10.1007/s10792-024-03077-x |